Drug cost increases will exceed 18% for 2000 – leading to a significant increase in total health plan costs - according to a study from the Segal Co., a consultant and actuary firm serving human resources, employee benefits and compensation programs in the U.S., Canada and abroad.
Drug cost increases will exceed 18% for 2000 â leading to a significant increase in total health plan costs - according to a study from the Segal Co., a consultant and actuary firm serving human resources, employee benefits and compensation programs in the U.S., Canada and abroad.
Highlights of the 2000 Segal Health Plan Cost Trend Survey include:
•Â Costs for prescription drugs in 2000 are expected to see the highest trend rates of all coverages studied.
•Â Non-network fee-for-service, preferred provider organization, point-of-service and health maintenance organization plans' claim costs trends are all projected to be higher for both the group of actives and retirees under age 65 and retirees age 65 and over in 2000 than 1999 projections.
•Â Trends in dental coverage will vary by plan type. 2000 projections will be lower than 1999 projections for non-network fee-for-service and network fee-for-service. Trend rates for prepaid dental plans, however, are projected to be higher in 2000 than in 1999.
According to Segal, the survey indicates that prescription drug rates of use will continue to increase at a rate double that of the HMO trend (for HMOs that include prescription drug coverage). At this rate of increase, prescription drug claim expenses are expected to approach 15% of active health plan costs and over 40% of retiree healthcare costs by the year 2001. But the company admits that the higher prescription rate may be due in part to a shift from medical and surgical treatments to drug therapies. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.